期刊文献+

冠心病经皮冠状动脉介入治疗术后氯吡格雷抵抗的临床分析 被引量:4

原文传递
导出
摘要 目的分析冠心病患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的情况。方法选取接受经皮冠状动脉介入治疗的冠心病患者120例,且均在术前和术后接受氯吡格雷治疗,根据患者是否出现氯吡格雷抵抗分为两组,实验组[出现氯吡格雷抵抗(术后5d血小板聚集抑制率≤10%)]33例,对照组(未出现氯吡格雷抵抗)87例。比较两组冠心病患者血小板活化水平的差异性。结果实验组术前、术后血小板活化标志物P.选择素(CD62p)和血小板膜暴露纤维蛋白原受体(PAC-1)水平均高于对照组(P均〈0.05)。结论冠心病患者经皮冠状动脉介入治疗后出现氯吡格雷抵抗可能与血小板活化水平有关,且会增加其心血管事件的发生概率。
出处 《中国实用医刊》 2018年第7期104-105,共2页 Chinese Journal of Practical Medicine
  • 相关文献

参考文献5

二级参考文献50

  • 1周健,吕虹,康熙雄.中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J].中国临床药理学与治疗学,2007,12(2):208-213. 被引量:84
  • 2Patti G, Colonna G, Pasceri V, et al. Randomized trial of high load- ing dose of clopidogrel for reduction of periprocedural myocardial infarc- tion in patients undergoing coronary intervention: results from the AR- MYDA -2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study [ J]. Circulation, 2005, 111 ( 16 ) : 2099 -2106.
  • 3Morrow DA, Scirica BM, Karwatowska - Prekopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non - ST - elevation acute coronary syndromes : the MERLIN - TIMI 36 random- ized trial [J]. JAMA, 2007, 297 (16): 1775-1783.
  • 4Godino C, Mendolicchio L, Figini F, et al. Comparison of VerifyNow - P2Y12 test and Flow Cytometry for monitoring individual platelet re- sponse to clopidogrel. What is the cut - off value for identifying patients who are low responders to clopidogrel therapy.'? [ J]. Throlnbosis Jour- nal, 2009, 7: 4. doi: 10. 1186/1477-9560-7-4.
  • 5Bertrand ME, Rupprecht HJ, Urban P, et al. Double -blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) [J]. Circulation, 2000, 102 (6): 624-629.
  • 6Aimldi F, Colombo A, Moriei N, et al. Incidence and predictors of drug - eluting stent throrobosis during and after discontinuation of thien-opyridine treatment [J]. Circulation, 2007, 116 (7): 745-754.
  • 7Lev EI, Patel RT, Maresh KJ, et al. Aspirin and ctopidogrel drug re- sponse in patients undergoing percutaneous coronary intervention the role of dual drug resistance[J]. J Am Coil Cardiol,2006,47 (1) :27 -33.
  • 8Matetzky S, Shenkman B, Guetta , et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in pa- tients with acute myocardial infarction [ J ]. Circulation, 2004, 109 (25) : 3171 -3175.
  • 9Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on - elopidogrel platelet reactivity over time in patients treated with per- cutaneous coronary intervention relationship with gene polyroorphisms and clinical outcome [J]. J Am Coil Cardiol, 2011, 57 (25): 2474 - 2483.
  • 10Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic elopidogrel therapy under- going percutaneous coronary intervention : is the current antiplatelet ther- apy adequate? [J]. J Am Coil Cardiol, 2007, 49 (6) : 657 -666.

共引文献55

同被引文献38

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部